We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Acer Therapeutics Com USD0.01 | NASDAQ:OPXA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.9699 | 0.95 | 1.00 | 0 | 01:00:00 |
Texas
|
76-0333165
|
|
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
2635 Technology Forest Blvd.
The Woodlands, Texas
|
77381
|
|
(Address of principal executive offices) | (Zip Code) |
Large accelerated filer | o | Accelerated filer | o |
Non-accelerated filer | o | Smaller reporting company | þ |
(Do not check if a smaller reporting company) |
Title of Securities
To Be Registered
|
Amount To
Be Registered
(1)
|
Proposed
Maximum Offering
Price Per Share
(2
)
|
Proposed
Maximum Aggregate
Offering Price
(2)
|
Amount of
Registration Fee
|
||||||||||||
Common stock, $.01 par value: To be issued under the Amended and Restated 2010 Stock Incentive Plan
|
650,000 | $ | 4.165 | $ | 2,707,250.00 | $ | 272.62 |
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933 (the “Securities Act”), this registration statement also covers an indeterminate number of additional shares of common stock to be offered or sold pursuant to the above-named plan that may be issued as a result of the anti-dilution and other adjustment provisions therein by reason of certain corporate transactions or events, including any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration which results in an increase in the number of the registrant’s outstanding shares of common stock.
|
(2)
|
Computed in accordance with Rules 457(c) and (h) under the Securities Act, solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the common stock as reported on the Nasdaq Capital Market on August 8, 2016.
|
(a)
|
Annual Report on Form 10-K for the
fiscal year ended December 31, 2015.
|
|
(b)
|
Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2016 and June 30, 2016.
|
|
(c)
|
Current Reports on Form 8-K filed on March 2, 2016, March 15, 2016 (except Item 2.02), March 25, 2016 and May 18, 2016.
|
|
|
(d)
|
The description of the Registrant’s Common Stock contained in the Registration Statement on Form 8-A (File No. 001-33004) filed on August 30, 2006, including any amendment or report filed for the purpose of updating such description.
|
OPEXA THERAPEUTICS, INC. | |||
Date
|
By:
|
/s/ Neil K. Warma | |
Neil K. Warma | |||
President, Chief Executive Officer | |||
and Acting Chief Financial Officer |
Name
|
Title
|
Date
|
||
/s/ Neil K. Warma
|
President, Chief Executive Officer, Acting Chief Financial Officer and Director
|
August 11, 2016
|
||
Neil K. Warma
|
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
|
|||
/s/ Tim Barabe
|
Director
|
August 11, 2016
|
||
Tim Barabe
|
||||
/s/ Hans-Peter Hartung
|
Director
|
August 11, 2016
|
||
Hans-Peter Hartung
|
||||
/s/ Gail J. Maderis |
Director
|
August 11, 2016
|
||
Gail J. Maderis | ||||
/s/ Michael S. Richman |
Director
|
August 11, 2016
|
||
Michael S. Richman | ||||
/s/ Scott B. Seaman |
Director
|
August 11, 2016
|
||
Scott B. Seaman | ||||
1 Year Acer Therapeutics Com USD0.01 Chart |
1 Month Acer Therapeutics Com USD0.01 Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions